GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
- Conditions
- HIV-1 Infection
- Interventions
- Drug: FTC/RPV/TDFDrug: EFV/FTC/TDF
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 799
- Registration Number
- NCT01309243
- Locations
- 🇦🇹
Universitätsklinikum Innsbruck Universitätsklinik für Dermatologie und Venerologie, Innsbruck, Austria
🇺🇸University of California, Davis, Sacramento, California, United States
🇺🇸Johns Hopkins Rockland Physicians Practice and Research Group at Greenspring Station, Lutherville, Maryland, United States
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
- Conditions
- Marginal Zone LymphomaSmall Lymphocytic LymphomaFollicular LymphomaIndolent Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT01306643
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
- Conditions
- HIV-1 Infection
- Interventions
- Drug: FTC/RPV/TDF
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT01286740
- Locations
- 🇺🇸
Atlanta ID Group, Atlanta, Georgia, United States
🇺🇸Be Well Medical Center, P.C., Berkley, Michigan, United States
🇺🇸Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
- Conditions
- Follicular LymphomaLymphoplasmacytic LymphomaMarginal Zone LymphomaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 125
- Registration Number
- NCT01282424
- Locations
- 🇺🇸
St. Jude Medical Center, Fullerton, California, United States
🇺🇸University of Medicine and Dentistry of NJ, New Brunswick, New Jersey, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 751
- Registration Number
- NCT01277601
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Private Practice, Philadelphia, Pennsylvania, United States
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: TF2/IMP288
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01273402
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: GS-9451 placeboBiological: Pegasys®
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 245
- Registration Number
- NCT01271790
- Locations
- 🇺🇸
Henry Ford Health System-Columbus center, Novi, Michigan, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Medical Associates Research Group, San Diego, California, United States
Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 26
- Registration Number
- NCT01270698
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 292
- Registration Number
- NCT01260350
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd., Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust, Christchurch, New Zealand
Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia
- Conditions
- Invasive Fungal Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 355
- Registration Number
- NCT01259713
- Locations
- 🇬🇧
Gilead Sciences, Cambridge, United Kingdom